▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Apr 3, 2014 by Todd Campbell

Better Buy: Laboratory Corp Vs. Quest Diagnostics

LabCorp (LH) and Quest Diagnostics (DGX) face off in the competitive lab services market. Since warmer weather boosts lab services volume, let's see if one is a better buy than the other.

Apr 3, 2014 by Todd Campbell

3 Stocks That Escaped Biotech's March Madness

Agios Pharmaceuticals (AGIO), Chimerix (CMRX), and Portola (PTLA) overcame widespread selling in biotech last month thanks to important, potentially game-changing therapies.

Apr 3, 2014 by Todd Campbell

3 Biggest Biotech Crashes in March

Here's why Celldex (CLDX), Acceleron (XLRN), and Newlink (NLNK) all tumbled in March.

Apr 1, 2014 by Todd Campbell

Here's Why Celgene Boosted Its Bet on Forma Therapeutics

Celgene (CELG) recently expanded its collaboration with emerging biotech Forma Therapeutics, but it's far from the only heavyweight teamed up with the company. Forma's collaborators include Novartis (NVS), Lilly (LLY), and Johnson & Johnson (JNJ) too.

Apr 1, 2014 by Todd Campbell

What You Need to Know About High Blood Pressure Drugs

Novartis' (NVS) highly successful ARB blood pressure drug Diovan will face generic competitors for the first time this year, increasing pressure for the company to bring LCZ696 to market.

Mar 30, 2014 by Todd Campbell

3 Dividend Stocks for Next Quarter

GlaxoSmithKline (GSK), Merck (MRK), and Quest DIagnositcs (DGX) not only offer compelling dividend yields but also a strong history of shareholder-friendly returns next quarter.

Mar 28, 2014 by Todd Campbell

Why 2014 May Be a Big Year for Opko Health, Inc.

Opko's (OPK) has a number of catalysts this year that could have a big impact on its biggest investor, Philip Frost; including a Tesaro's (TSRO) potential FDA filing for Rolapitant.

Mar 28, 2014 by Todd Campbell

4 Disruptive Stocks Biotechs Depend On

Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.

Mar 28, 2014 by Todd Campbell

Supreme Court Ignores Teva Pharmaceuticals Ltd's Pleas for Help

Teva faces patent expiration on its $4 billion-a-year Copaxone in May.

Mar 28, 2014 by Todd Campbell

Did Veeva Systems Just Get Cheap?

Veeva shares have fallen nearly 50% from their post-IPO peak, but that doesn't necessarily make shares a bargain.

Mar 27, 2014 by Todd Campbell

Is It Time to Buy These 2 Cancer-Fighting Companies?

Seattle Genetics' (SGEN) and Pharmacyclics' (PCYC) shares are tumbling, despite promising cancer drugs that could see significant sales growth.

Mar 27, 2014 by Todd Campbell

Here's How Sanofi Hopes to Survive Post-Lantus

Sanofi (SNY) hopes its promising new diabetes drug U300 will protect its top line when Lantus loses patent protection in 2015.

Mar 27, 2014 by Todd Campbell

Better Buy: Gilead or AbbVie

Gilead (GILD) and AbbVie (ABBV) are set to face off against one another with new therapies for hepatitis C, but is one a better buy than the other?

Mar 26, 2014 by Todd Campbell

Dividend Derby: AbbVie Vs. Pfizer

AbbVie (ABBV) and Pfizer (PFE) are staples in dividend portfolios and both will need new products to overcome patent risks over the next three years.

Mar 26, 2014 by Todd Campbell

Watch Out AbbVie, Here Comes Celgene

AbbVie's (ABBV) Humira is facing new competition in psoriatic arthritis following the FDA's recent approval of Celgene's (CELG) Otezla.

Mar 24, 2014 by Todd Campbell

1 Piece of News That Could Move Exelixis

Data from Exelixis (EXEL) phase 3 trial of Cometriq in prostate cancer should be released soon. If results are positive, Johnson & Johnson (JNJ), Medivation (MDVN), and Bayer (BAYRY) may face a new competitor.

Mar 24, 2014 by Todd Campbell

Better Buy: Eli Lilly & Co. or AstraZeneca plc?

Eli Lilly and AstraZeneca are leaders in diabetes treatment. Both are seeing sales fall as blockbuster drugs lose patent protection, but is one of these companies a better buy than the other?

Mar 22, 2014 by Todd Campbell

Could Isis Threaten Regeneron and Novartis?

Investors will get data from a mid stage trial for iCo-007 as a treatment for DME in April. If results are solid, a move into phase 3 could eventually position Isis (ISIS) against Regeneron (REGN) and Novartis (NVS).

Mar 21, 2014 by Todd Campbell

Here's How Amgen May Help Merck

Studies using Amgen's (AMGN) PCSK9 drug Evolocumab (AMG-145) alongside Merck's (MRK) Zetia could boost Zetia sales.

Mar 21, 2014 by Todd Campbell

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters

Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services